----

----

|   | x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|---|-----------------------------------------------------------------------------------------|

|   | o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|---|------------------------------------------------------------------------------------------|

|                       DELAWARE                       |                       22-3367588                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (State or other jurisdiction of                                                                                                                                                                                                                                                  | (I.R.S. Employer                                                                                                                                                                                                                                                                   |
| incorporation or organization)                                                                                                                                                                                                                                                   | Identification Number)                                                                                                                                                                                                                                                             |

| 100 Matawan Road, Suite 420                       |                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Matawan, NJ                                                                                                                                                     |                       07747                       |
| (Address of principal executive offices)                                                                                                                        | (Zip Code)                                                                                                                                                                                                                                                                    |

| Large accelerated filer o                                                              | Accelerated filer o         |
|----------------------------------------------------------------------------------------|-----------------------------|
| Non-accelerated filer   o (Do not check if a smaller reporting company) | Smaller reporting company x |

----

| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 3                                                                                       |
|------------------------------------------------------|-----------------------------------------------------------------------------------------|
|                                                 |                                                                                    |   |   |
| PART I.   FINANCIAL INFORMATION       |                                                                                    |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 1.                                                                                 | FINANCIAL STATEMENTS |   |
|                                                 |                                                                                    |   |   |
|                                                 | Balance Sheets as of March 31, 2010 (Unaudited) and December 31, 2009                   | 4 |
|                                                 |                                                                                    |   |   |
|                                                 | Statements of Operations (Unaudited) for the three months ended March 31, 2010 and 2009 | 5 |
|                                                 |                                                                                    |   |   |
|                                                 | Statements of Cash Flows (Unaudited) for the three months ended March 31, 2010 and 2009 | 6 |
|                                                 |                                                                                    |   |   |
|                                                 | Notes to Unaudited Financial Statements                                                 | 7 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 2.                                                                                 | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 13 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 3.                                                                                 | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 15 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 4T.                                                                                | CONTROLS AND PROCEDURES | 15 |
|                                                 |                                                                                    |   |   |
| PART II.  OTHER INFORMATION                |                                                                                    |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 1.                                                                                 | LEGAL PROCEEDINGS | 16 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 2.                                                                                 | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 16 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 3.                                                                                 | DEFAULTS UPON SENIOR SECURITIES | 16 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 4.                                                                                 | REMOVED AND RESERVED | 16 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 5.                                                                                 | OTHER INFORMATION | 16 |
|                                                 |                                                                                    |   |   |
|                                                 | ITEM 6.                                                                                 | EXHIBITS | 16 |
|                                                 |                                                                                    |   |   |
| SIGNATURES                                           | 16                                                                                      |

----

|   | ● | The development, testing, and commercialization of new products and the expansion of markets for our current products; |
|--------|---------|------------------------------------------------------------------------------------------------------------------------|
|   | ● | The receipt of royalty payments from our agreements with business partners;                                            |
|   | ● | Implementing aspects of our business plan;                                                                             |
|   | ● | Financing goals and plans;                                                                                             |
|   | ● | Our existing cash and whether and how long these funds will be sufficient to fund our operations; and                  |
|   | ● | Our raising of additional capital through future equity financings.                                                    |

----

| PACIFICHEALTH LABORATORIES, INC.                                                    |   |
|-------------------------------------------------------------------------------------|--------|
| BALANCE SHEETS                                                                      |   |
|                                                                                |   |   |   |   |   |   |
| ASSETS                                                                              |   |
|                                                                                |   | March 31, |   |   | December 31, |   |
|                                                                                |   | 2010 |   |   | 2009 |   |
|                                                                                |   | (Unaudited) |   |   |   |   |
| Current assets:                                                                     |   |   |   |   |   |   |
| Cash and cash equivalents                                                           |   | $ | 251,030 |   |   | $ | 281,159 |   |
| Other short-term investments                                                        |   |   | 175,000 |   |   |   | 175,000 |   |
| Accounts receivable, net                                                            |   |   | 965,424 |   |   |   | 763,288 |   |
| Inventories, net                                                                    |   |   | 650,646 |   |   |   | 806,212 |   |
| Prepaid expenses                                                                    |   |   | 80,487 |   |   |   | 92,702 |   |
| Tax loss receivable                                                                 |   |   | - |   |   |   | 303,931 |   |
| Total current assets                                                                |   |   | 2,122,587 |   |   |   | 2,422,292 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Property and equipment, net                                                         |   |   | 91,163 |   |   |   | 110,904 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Deposits                                                                            |   |   | 10,895 |   |   |   | 10,895 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Total assets                                                                        |   | $ | 2,224,645 |   |   | $ | 2,544,091 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Current liabilities:                                                                |   |   |   |   |   |   |   |   |
| Line of credit                                                                      |   | $ | 87,500 |   |   | $ | - |   |
| Notes payable                                                                       |   |   | - |   |   |   | 12,182 |   |
| Accounts payable and accrued expenses                                               |   |   | 965,069 |   |   |   | 1,042,051 |   |
| Deferred revenue                                                                    |   |   | 207,152 |   |   |   | 306,239 |   |
| Total current liabilities                                                           |   |   | 1,259,721 |   |   |   | 1,360,472 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Commitments                                                                         |   |   |   |   |   |   |   |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Stockholders' equity:                                                               |   |   |   |   |   |   |   |   |
| Common stock, $.0025 par value; authorized                                          |   |   |   |   |   |   |   |   |
| 50,000,000 shares; issued and outstanding:                                          |   |   |   |   |   |   |   |   |
| 16,035,988  and 15,624,017 shares, respectively                           |   |   | 40,090 |   |   |   | 39,060 |   |
| Additional paid-in capital                                                          |   |   | 20,081,104 |   |   |   | 20,031,599 |   |
| Accumulated deficit                                                                 |   |   | (19,156,270 | ) |   |   | (18,887,040 | ) |
|                                                                                |   |   | 964,924 |   |   |   | 1,183,619 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders' equity                                          |   | $ | 2,224,645 |   |   | $ | 2,544,091 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| The accompanying notes should be read in conjunction with the financial statements. |   |

----

| PACIFICHEALTH LABORATORIES, INC.                                                    |   |
|-------------------------------------------------------------------------------------|--------|
| STATEMENTS OF OPERATIONS                                                            |   |
| FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009                                  |   |
| (UNAUDITED)                                                                         |   |
|                                                                                |   |   |   |   |   |   |
|                                                                                |   | Three Months |   |
|                                                                                |   | Ended March 31, |   |
|                                                                                |   | 2010 |   |   | 2009 |   |
| Revenue:                                                                            |   |   |   |   |   |   |
| Net product sales                                                                   |   | $ | 1,650,265 |   |   | $ | 1,695,618 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Cost of goods sold                                                                  |   |   | 909,379 |   |   |   | 953,997 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Gross profit                                                                        |   |   | 740,886 |   |   |   | 741,621 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Operating expenses:                                                                 |   |   |   |   |   |   |   |   |
| Sales and marketing                                                                 |   |   | 235,085 |   |   |   | 316,108 |   |
| General and administrative                                                          |   |   | 774,150 |   |   |   | 832,482 |   |
|                                                                                |   |   | 1,009,235 |   |   |   | 1,148,590 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Loss before other (expense) income and provision for                                |   |   |   |   |   |   |   |   |
| income taxes                                                                        |   |   | (268,349 | ) |   |   | (406,969 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Other (expense) income:                                                             |   |   |   |   |   |   |   |   |
| Interest income                                                                     |   |   | 228 |   |   |   | 2,291 |   |
| Interest expense                                                                    |   |   | (1,109 | ) |   |   | (787 | ) |
|                                                                                |   |   | (881 | ) |   |   | 1,504 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Loss before provision for income taxes                                              |   |   | (269,230 | ) |   |   | (405,465 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Provision for income taxes                                                          |   |   | - |   |   |   | - |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Net loss                                                                            |   | $ | (269,230 | ) |   | $ | (405,465 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Net loss per common share - basic and diluted                                       |   | $ | (0.02 | ) |   | $ | (0.03 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding - basic and diluted                             |   |   | 15,684,010 |   |   |   | 14,459,492 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| The accompanying notes should be read in conjunction with the financial statements. |   |

----

| PACIFICHEALTH LABORATORIES, INC.                                                    |   |
|-------------------------------------------------------------------------------------|--------|
| STATEMENTS OF CASH FLOWS                                                            |   |
| FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009                                  |   |
| (UNAUDITED)                                                                         |   |
|                                                                                |   |   |   |   |   |   |
|                                                                                |   | 2010 |   |   | 2009 |   |
| Cash flows from operating activities:                                               |   |   |   |   |   |   |
| Net loss                                                                            |   | $ | (269,230 | ) |   | $ | (405,465 | ) |
| Adjustments to reconcile net loss to net                                            |   |   |   |   |   |   |   |   |
| cash used in operating activities:                                                  |   |   |   |   |   |   |   |   |
| Depreciation                                                                        |   |   | 35,219 |   |   |   | 46,755 |   |
| Allowance for doubtful accounts                                                     |   |   | 3,000 |   |   |   | 3,000 |   |
| Equity instrument-based expense                                                     |   |   | 41,945 |   |   |   | 69,498 |   |
| Changes in assets and liabilities:                                                  |   |   |   |   |   |   |   |   |
| Accounts receivable                                                                 |   |   | (205,136 | ) |   |   | (407,272 | ) |
| Inventories                                                                         |   |   | 155,566 |   |   |   | (5,534 | ) |
| Prepaid expenses                                                                    |   |   | 12,215 |   |   |   | 9,536 |   |
| Tax loss receivable                                                                 |   |   | 303,931 |   |   |   | - |   |
| Accounts payable and accrued expenses                                               |   |   | (68,392 | ) |   |   | 325,159 |   |
| Deferred revenue                                                                    |   |   | (99,087 | ) |   |   | 26,920 |   |
| Net cash used in operating activities                                               |   |   | (89,969 | ) |   |   | (337,403 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Cash flows from investing activities:                                               |   |   |   |   |   |   |   |   |
| Proceeds from sales of other short-term investments                                 |   |   | - |   |   |   | 25,000 |   |
| Purchase of property and equipment                                                  |   |   | (15,478 | ) |   |   | (12,205 | ) |
| Net cash (used in) provided by investing activities                                 |   |   | (15,478 | ) |   |   | 12,795 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Cash flows from financing activities:                                               |   |   |   |   |   |   |   |   |
| Borrowings on line of credit                                                        |   |   | 87,500 |   |   |   | - |   |
| Repayments of notes payable                                                         |   |   | (12,182 | ) |   |   | (28,779 | ) |
| Net cash provided by (used in) financing activities                                 |   |   | 75,318 |   |   |   | (28,779 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Net decrease in cash and cash equivalents                                           |   |   | (30,129 | ) |   |   | (353,387 | ) |
|                                                                                |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, beginning balance                                        |   |   | 281,159 |   |   |   | 888,993 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, ending balance                                           |   | $ | 251,030 |   |   | $ | 535,606 |   |
|                                                                                |   |   |   |   |   |   |   |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Supplemental disclosures of cash flow information:                                  |   |   |   |   |   |   |   |   |
| Cash paid for interest                                                              |   | $ | 1,109 |   |   | $ | 787 |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Cash paid for income taxes                                                          |   | $ | 5,295 |   |   | $ | - |   |
|                                                                                |   |   |   |   |   |   |   |   |
| Non-cash operating activity:                                                        |   |   |   |   |   |   |   |   |
| Issuance of common stock as payment for consulting services                         |   | $ | 8,590 |   |   | $ | - |   |
|                                                                                |   |   |   |   |   |   |   |   |
| The accompanying notes should be read in conjunction with the financial statements. |   |

----

----

|                          |   | March 31,   |    |   |         |   |
|-------------------------------|--------|-------------|---------|--------|--------------|--------|
|                          |   | 2010        |    |   | December 31, |   |
|                          |   | (Unaudited) |    |   | 2009         |   |
| Raw materials                 |   | $           | -       |   |         | $      | - |   |
| Work-in-process               |   |        | -       |   |         |   | - |   |
| Packaging supplies            |   |        | 84,577  |   |         |   | 80,611 |   |
| Finished goods                |   |        | 500,798 |   |         |   | 645,095 |   |
| Finished goods on consignment |   |        | 65,271  |   |         |   | 80,506 |   |
|                          |   | $           | 650,646 |   |         | $      | 806,212 |   |

|                          |   | March 31,   |      |   |         |   |
|-------------------------------|--------|-------------|-----------|--------|--------------|--------|
|                          |   | 2010        |      |   | December 31, |   |
|                          |   | (Unaudited) |      |   | 2009         |   |
| Furniture and equipment       |   | $           | 818,017   |   |         | $      | 815,724 |   |
| Molds and dies                |   |        | 231,731   |   |         |   | 218,546 |   |
|                          |   |        |      |   |         |   |   |   |
|                          |   |        | 1,049,748 |   |         |   | 1,034,270 |   |
| Less accumulated depreciation |   |        | 958,585   |   |         |   | 923,366 |   |
|                          |   | $           | 91,163    |   |         | $      | 110,904 |   |

|                |   | March 31,   |    |   |         |   |
|---------------------|--------|-------------|---------|--------|--------------|--------|
|                |   | 2010        |    |   | December 31, |   |
|                |   | (Unaudited) |    |   | 2009         |   |
| Trade payables      |   | $           | 767,850 |   |         | $      | 826,236 |   |
| Accrued expenses    |   |        | 162,778 |   |         |   | 180,086 |   |
| Commissions payable |   |        | 19,815  |   |         |   | 23,265 |   |
| Deferred rent       |   |        | 14,626  |   |         |   | 12,464 |   |
|                |   | $           | 965,069 |   |         | $      | 1,042,051 |   |

----

|                             |   | Three Months    |   |
|----------------------------------|--------|-----------------|--------|
|                             |   | Ended March 31, |   |
|                             |   | 2010            |   |   | 2009 |   |
|                             |   |            |   |   |   |   |
| Employee compensation            |   | $               | 39,198 |   |   | $ | 66,823 |   |
| Consultant/endorser compensation |   | 2,747           |   |   |   | 2,675 |   |
|                             |   | $               | 41,945 |   |   | $ | 69,498 |   |

|                        |   |   |      |   |      |   |   | Weighted-    |   |   |      |   |
|-----------------------------|--------|--------|-----------|--------|-----------|--------|--------|--------------|--------|--------|-----------|--------|
|                        |   |   |      |   | Weighted- |   |   | Average      |   |   |      |   |
|                        |   |   |      |   | Average   |   |   | Remaining    |   |   | Aggregate |   |
|                        |   |   |      |   | Exercise  |   |   | Contractual  |   |   | Intrinsic |   |
| Options                     |   | Shares |      |   | Price     |   |   | Term (Years) |   |   | Value     |   |
| Balance, January 1, 2010    |   |   | 2,438,500 |   |      | $      | 0.64   |         |   |   |      |   |   |   |   |   |
| Granted during the period   |   |   | 250,000   |   |      |   | 0.12   |         |   |   |      |   |   |   |   |   |
| Exercised during the period |   |   | -         |   |      |   | -      |         |   |   |      |   |   |   |   |   |
| Forfeited during the period |   |   | (541,666  | )      |      |   | 0.53   |         |   |   |      |   |   |   |   |   |
| Outstanding, March 31, 2010 |   |   | 2,146,834 |   |      | $      | 0.61   |         |   |   | 1.96      |   |   |   | $-0- |   |
| Exercisable, March 31, 2010 |   |   | 1,554,334 |   |      | $      | 0.77   |         |   |   | 1.18      |   |   |   | $-0- |   |

----

|                        |   |   |      |   | Weighted       |   |   |
|-----------------------------|--------|--------|-----------|--------|----------------|--------|--------|
|                        |   |   |      |   | Average        |   |   |
|                        |   |   |      |   | Exercise Price |   |   |
|                        |   |   |      |   | Per Share      |   |   |
| Non-vested Options          |   | Shares |      |   | Outstanding    |   |   |
| Non-vested, January 1, 2010 |   |   | 1,129,583 |   |           | $      | 0.46   |   |   |
| Granted during the period   |   |   | 250,000   |   |           |   | 0.12   |   |   |
| Vested during the period    |   |   | (245,417  | )      |           |   | 0.58   |   |   |
| Forfeited during the period |   |   | (541,666  | )      |           |   | 0.53   |   |   |
| Non-vested, March 31, 2010  |   |   | 592,500   |   |           | $      | 0.21   |   |   |

|                        |   |   |    |   | Weighted- |   |   |      |   |   |
|-----------------------------|--------|--------|---------|--------|-----------|--------|--------|-----------|--------|--------|
|                        |   |   |    |   | Average   |   |   | Aggregate |   |   |
|                        |   |   |    |   | Exercise  |   |   | Intrinsic |   |   |
| Warrants                    |   | Shares |    |   | Price     |   |   | Value     |   |   |
| Balance, January 1, 2010    |   |   | 402,500 |   |      | $      | 0.14   |      |   |   |   |   |
| Granted during the period   |   |   | 10,000  |   |      |   | 0.12   |      |   |   |   |   |
| Expired during the period   |   |   | -       |   |      |   | -      |      |   |   |   |   |
| Outstanding, March 31, 2010 |   |   | 412,500 |   |      | $      | 0.14   |      |   | $      | -0- |   |   |
| Exercisable, March 31, 2010 |   |   | 113,332 |   |      | $      | 0.14   |      |   | $      | -0- |   |   |

|                        |   |   |    |   | Weighted       |   |   |
|-----------------------------|--------|--------|---------|--------|----------------|--------|--------|
|                        |   |   |    |   | Average        |   |   |
|                        |   |   |    |   | Exercise Price |   |   |
|                        |   |   |    |   | Per Share      |   |   |
| Non-vested Warrants         |   | Shares |    |   | Outstanding    |   |   |
| Non-vested, January 1, 2010 |   |   | 289,343 |   |           | $      | 0.14   |   |   |
| Granted during the period   |   |   | 10,000  |   |           |   | 0.12   |   |   |
| Vested during the period    |   |   | (175    | )      |           |   | 0.14   |   |   |
| Forfeited during the period |   |   | -       |   |           |   | -      |   |   |
| Non-vested, March 31, 2010  |   |   | 299,168 |   |           | $      | 0.14   |   |   |

----

----

----

| Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|---------|---------------------------------------------------------------------------------------------|

| (a) | Introduction |
|-----|--------------|

----

| (b) | Results of Operations – Three Months Ended March 31, 2010 and 2009 |
|-----|--------------------------------------------------------------------------|

| (c) | Liquidity and Capital Resources |
|-----|---------------------------------|

----

| (d) | Off-Balance Sheet Arrangements |
|-----|--------------------------------|

| (e) | Going Concern |
|-----|---------------|

| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
|---------|------------------------------------------------------------|

| ITEM 4T. | CONTROLS AND PROCEDURES |
|----------|-------------------------|

----

| PART II.           | OTHER INFORMATION                                           |
|--------------------|-------------------------------------------------------------|
|               |                                                        |
| ITEM 1.            | LEGAL PROCEEDINGS                                           |
|               |                                                        |
|               | None.                                                       |
|               |                                                        |
| ITEM  2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
|               |                                                        |
|               | None.                                                       |
|               |                                                        |
| ITEM 3.            | DEFAULTS UPON SENIOR SECURITIES                             |
|               |                                                        |
|               | None.                                                       |
|               |                                                        |
| ITEM 4.            | REMOVED AND RESERVED                                        |
|               |                                                        |
| ITEM 5.            | OTHER INFORMATION                                           |
|               |                                                        |
|               | None.                                                       |
|               |                                                        |
| ITEM 6.            | EXHIBITS                                                    |
|               |                                                        |

| ExhibitNumber | Description of Exhibit                                                                                                          |
|---------------|---------------------------------------------------------------------------------------------------------------------------------|
|          |                                                                                                                            |
| 31.1*         | Rule 13a-14(a) Certification of Chief Executive Officer                                                                         |
|          |                                                                                                                            |
| 31.2*         | Rule 13a-14(a) Certification of Chief Financial Officer                                                                         |
|          |                                                                                                                            |
| 32**          | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

| *  | Filed herewith     |
|----|--------------------|
| ** | Furnished herewith |

|   | PACIFICHEALTH LABORATORIES, INC.                                                                                                                     |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                 |   |
|   |                                                                                                                                                 |   |
|   | By: /S/ STEPHEN P. KUCHEN                                                                                                                            |   |
|   | STEPHEN P. KUCHEN                                                                                                                                    |   |
|   | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)                                                               |   |
|   |                                                                                                                                                 |   |
|   | Date:May 6, 2010                       |   |